Overview

Effects of p38 MAPK Inhibitor POLB 001 on in Vivo LPS Challenge Responses

Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
A single center trial to evaluate the effect of POLB 001 on inflammatory responses following an intradermal LPS challenge in healthy volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Poolbeg Pharma plc